Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 24, 2015, Pages 4841-4850

  Xu, L H ^a,b   Guo, Y ^b   Cen, J N ^c   Yan, W Y ^c   He, H L ^a   Niu, Y N ^d   Lin, Y X ^c   Chen, C S ^e   Hu, S Y ^a  

^a CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Department of Ultrasound The First People s Hospital of Lianyungang   (China)

^c SOOCHOW UNIVERSITY   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

^e LOMA LINDA UNIVERSITY   (United States)

Author keywords

Diagnosis; MiR 155; MiR 25; Pediatric acute myeloid leukemia; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CD135 ANTIGEN; LACTATE DEHYDROGENASE; MICRORNA; MICRORNA 155; MICRORNA 25; UNCLASSIFIED DRUG; MIRN155 MICRORNA, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHINESE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ONCOGENE C KIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION SYSTEM; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ACUTE MYELOID LEUKEMIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; GENE EXPRESSION REGULATION; GENETICS; INFANT; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BONE MARROW; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MICRORNAS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84966430683     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. DASH A, GILLILAND DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 49-64.
2. MANOLA KN. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009; 83: 391-405.
3. KASPERS GJ, CREUTZIG U. Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 2005; 19: 2025-2029.
4. HARRISON CJ, HILLS RK, MOORMAN AV, GRIMWADE DJ, HANN I, WEBB DK, WHEATLEY K, DE GRAAF SS, VAN DEN BERG E, BURNETT AK, GIBSON BE. Cytogenetics of childhood acute myeloid leukemia: United kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol 2010; 28: 2674-2681.
5. BURNETT A, WETZLER M, LOWENBERG B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
6. LI L, XIAO ZJ. Research update on pharmacogenomics in acute leukemia-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 704-711.
7. PUI CH, CARROLL WL, MESHINCHI S, ARCECI RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011; 29: 551-565.
8. MOORE AS, KEARNS PR, KNAPPER S, PEARSON AD, ZWAAN CM. Novel therapies for children with acute myeloid leukaemia. Leukemia 2013; 27: 1451-1460.
9. CHEN CZ. Micrornas as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
10. GARZON R, GAROFALO M, MARTELLI MP, BRIESEWITZ R, WANG L, FERNANDEZ-CYMERING C, VOLINIA S, LIU CG, SCHNITTGER S, HAFERLACH T, LISO A, DIVERIO D, MANCINI M, MELONI G, FOA R, MARTELLI MF, MECUCCI C, CROCE CM, FALINI B. Distinctive microrna signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008; 105: 3945-3950.
11. MI S, LU J, SUN M, LI Z, ZHANG H, NEILLY MB, WANG Y, QIAN Z, JIN J, ZHANG Y, BOHLANDER SK, LE BEAU MM, LARSON RA, GOLUB TR, ROWLEY JD, CHEN J. Microrna expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007; 104: 19971-19976.
12. ZHANG W, ZANG J, JING X, SUN Z, YAN W, YANG D, SHEN B, GUO F. Identification of candidate mirna biomarkers from mirna regulatory network with application to prostate cancer. J Transl Med 2014; 12: 66.
13. YAN W, XU L, SUN Z, LIN Y, ZHANG W, CHEN J, HU S, SHEN B. Microrna biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model. Oncotarget 2015; 6: 26424-26436.
14. O'CONNELL RM, RAO DS, CHAUDHURI AA, BOLDIN MP, TAGANOV KD, NICOLL J, PAQUETTE RL, BALTIMORE D. Sustained expression of microrna-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-594.
15. BIRKS DK, BARTON VN, DONSON AM, HANDLER MH, VIBHAKAR R, FOREMAN NK. Survey of microrna expression in pediatric brain tumors. Pediatr Blood Cancer 2011; 56: 211-216.
16. SCHOTTE D, LANGE-TURENHOUT EA, STUMPEL DJ, STAM RW, BUIJS-GLADDINES JG, MEIJERINK JP, PIETERS R, DEN BOER ML. EXPRESSION OF MIR-196B IS NOT EXCLUSIVELY MLL-DRIVEN BUT IS ESPECIALLY LINKED TO ACTIVATION OF HOXA GENES IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA. HAEMATOLOGICA 2010;95:1675-1682.
17. SUBSPECIALTY GROUP OF HEMATOLOGY DISEASES, THE SOCIETY OF PEDIATRICS, CHINESE MEDICAL ASSOCIATION. Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood. Chinese Journal of Pediatrics 2006; 44: 877-878.
18. LIVAK KJ, SCHMITTGEN TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods 2001; 25: 402-408.
19. VARDIMAN JW, THIELE J, ARBER DA, BRUNNING RD, BOROWITZ MJ, PORWIT A, HARRIS NL, LE BEAU MM, HELLSTROM-LINDBERG E, TEFFERI A, BLOOMFIELD CD. The 2008 revision of the world health organization (who) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
20. NCCN: NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®). Acute myeloid leukemia version 1. 2015 [eb/ol]. National Comprehensive Cancer Network. Inc. 2014. http://www.nccn.org/
21. LU J, GETZ G, MISKA EA, ALVAREZ-SAAVEDRA E, LAMB J, PECK D, SWEET-CORDERO A, EBERT BL, MAK RH, FERRANDO AA, DOWNING JR, JACKS T, HORVITZ HR, GOLUB TR. Microrna expression profiles classify human cancers. Nature 2005; 435: 834-838.
22. JOYCE CE, NOVINA CD. Mir-155 in acute myeloid leukemia: not merely a prognostic marker? J Clin Oncol 2013; 31: 2219-2221.
23. ZHI F, CAO X, XIE X, WANG B, DONG W, GU W, LING Y, WANG R, YANG Y, LIU Y. Identification of circulating micrornas as potential biomarkers for detecting acute myeloid leukemia. PloS One 2013; 8: e56718.
24. ZHU YD, WANG L, SUN C, FAN L, ZHU DX, FANG C, WANG YH, ZOU ZJ, ZHANG SJ, LI JY, XU W. Distinctive microrna signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol 2012; 29: 2323-2331.
25. MARCUCCI G, MAHARRY KS, METZELER KH, VOLINIA S, WU YZ, MROZEK K, NICOLET D, KOHLSCHMIDT J, WHITMAN SP, MENDLER JH, SCHWIND S, BECKER H, EISFELD AK, CARROLL AJ, POWELL BL, KOLITZ JE, GARZON R, CALIGIURI MA, STONE RM, BLOOMFIELD CD. Clinical role of micrornas in cytogenetically normal acute myeloid leukemia: Mir-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086-2093.
26. ABU-DUHIER FM, GOODEVE AC, WILSON GA, GARI MA, PEAKE IR, REES DC, VANDENBERGHE EA, WINSHIP PR, REILLY JT. Flt3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-195.
27. SHIMADA A, TAKI T, TABUCHI K, TAWA A, HORIBE K, TSUCHIDA M, HANADA R, TSUKIMOTO I, HAYASHI Y. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806-1809.
28. MANARA E, BISIO V, MASETTI R, BEQIRI V, RONDELLI R, MENNA G, MICALIZZI C, SANTORO N, LOCATELLI F, BASSO G, PIGAZZI M. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the aieop aml 2002/01 trial: Screening and prognostic impact of c-kit mutations. Leukemia 2014; 28: 1132-1134.
29. LI W, ZHANG L, HUANG L, MI Y, WANG J. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leuk Res 2012; 36: 186-191.
30. MASETTI R, VENDEMINI F, ZAMA D, BIAGI C, GASPERINI P, PESSION A. All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. Expert Rev Anticancer Ther 2012; 12: 1191-1204.
31. ABAZA H, GHANEM A, JMAL A, BOUSSEN H, HARZALLAH L, RAHAL K, GUEMIRA F. Importance of determination of c reactive protein (crp), carcinoembryonic antigen (cea) and lactic dehydrogenase (ldh) in colorectal cancer. Tunis Med 2010; 88: 409-413.
32. MESHINCHI S, ARCECI RJ. Prognostic factors and riskbased therapy in pediat r ic acute myeloid leukemia. Oncologist 2007; 12: 341-355.
33. PETROCCA F, VECCHIONE A, CROCE CM. Emerging role of mir-106b-25/mir-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008; 68: 8191-8194.
34. WANG Y, LI Z, HE C, WANG D, YUAN X, CHEN J, JIN J. Micrornas expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 2010; 44: 191-197.
35. LI X, YANG C, WANG X, ZHANG J, ZHANG R, LIU R. The expression of mir-25 is increased in colorectal cancer and is associated with patient prognosis. Med Oncol 2014; 31: 781.
36. GREK M, PIEKARSKA A, BARTKOWIAK J, FENDLER W, KUYDOWICZ J, WROBLEWSKI P, PARADOWSKI M, SIDORKIEWICZ M. Coordinated increase of mirna-155 and mirna-196b expression correlates with the detection of the antigenomic strand of hepatitis c virus in peripheral blood mononuclear cells. Int J Mol Med 2011; 28: 875-880.